PMID- 22239020
OWN - NLM
STAT- MEDLINE
DCOM- 20120213
LR  - 20131121
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 57
IP  - 11-12
DP  - 2011
TI  - Reduced levels of anti-MDA LDL antibodies in patients with carbohydrate 
      metabolism disorders.
PG  - 901-7
AB  - BACKGROUND: Diabetic patients undergoing percutaneous coronary intervention (PCI) 
      have a worse prognosis than non-diabetic patients. The anti-oxidized LDL 
      antibodies (anti-LDLox ab) have recently been suggested to be protective against 
      the development of diabetes. The aim of this study was to compare the levels of 
      IgG and IgM anti-oxidized LDL antibodies with reference to the new diagnostic 
      criteria for carbohydrate metabolism disorders after an oral glucose tolerance 
      test (OGTT) in hospitalized patients scheduled to undergo percutaneous coronary 
      intervention. METHODS: We undertook a cross-sectional study of 110 patients 
      undergoing PCI. The patients were classified as being normal (oral glucose test 
      tolerance normal, OGTT-N), or having impaired glucose tolerance (IGT) or type 2 
      diabetes mellitus (T2DM) according to their glucose levels at baseline and after 
      an OGTT. RESULTS: An inverse slope was found in the levels of IgG anti-oxidized 
      LDL antibodies between the OGTT-N patients (optical density (OD) = 0.109) and the 
      patients with IGT (OD = 0.099) or T2DM (OD = 0.084) (p = 0.019). An inverse 
      correlation was also detected between the levels of IgG anti-oxidized LDL 
      antibodies and baseline glycemia (r = -0.23, p = 0.018). CONCLUSIONS: Patients 
      with coronary disease and carbohydrate metabolism disorders have much lower 
      levels of IgG anti-oxidized LDL antibodies than normoglycemic patients.
FAU - Garrido-Sanchez, Lourdes
AU  - Garrido-Sanchez L
AD  - CIBERDEM, Hospital Universitari Joan XXIII, IISPV, Tarragona, Spain. 
      lourgarrido@gmail.com
FAU - Garcia-Pinilla, J M
AU  - Garcia-Pinilla JM
FAU - Jimenez-Navarro, Manuel
AU  - Jimenez-Navarro M
FAU - Fernandez-Pastora, Julia
AU  - Fernandez-Pastora J
FAU - Alonso-Briales, Juan H
AU  - Alonso-Briales JH
FAU - Hernandez-Garcia, Jose M
AU  - Hernandez-Garcia JM
FAU - De-Teresa-Galvan, Eduardo
AU  - De-Teresa-Galvan E
FAU - Tinahones, Francisco J
AU  - Tinahones FJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Autoantigens)
RN  - 0 (Blood Glucose)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (malondialdehyde-low density lipoprotein, human)
RN  - 4Y8F71G49Q (Malondialdehyde)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angioplasty, Balloon, Coronary
MH  - Antibody Specificity
MH  - Autoantigens/*immunology
MH  - Blood Glucose/analysis
MH  - Coronary Disease/blood/complications/immunology
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/blood/complications/diagnosis/*immunology
MH  - Female
MH  - Glucose Intolerance/blood/complications/diagnosis/*immunology
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Hypercholesterolemia/blood/complications/immunology
MH  - Hypertension/blood/complications/immunology
MH  - Immunoglobulin G/blood/*immunology
MH  - Lipoproteins, LDL/*immunology
MH  - Male
MH  - Malondialdehyde/*analogs & derivatives/immunology
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Prognosis
MH  - Renal Insufficiency/blood/complications/immunology
EDAT- 2012/01/14 06:00
MHDA- 2012/02/14 06:00
CRDT- 2012/01/14 06:00
PHST- 2012/01/14 06:00 [entrez]
PHST- 2012/01/14 06:00 [pubmed]
PHST- 2012/02/14 06:00 [medline]
PST - ppublish
SO  - Clin Lab. 2011;57(11-12):901-7.